Here's Why Conmed (CNMD) is a Strong Momentum Stock

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service aims to help investors become more informed and confident in their investment decisions [1] Group 2: Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [3] Group 3: Value Score - The Value Style Score focuses on identifying undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Group 4: Growth Score - The Growth Style Score assesses a company's financial health and future outlook by examining projected and historical earnings, sales, and cash flow [4] Group 5: Momentum Score - The Momentum Style Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of market trends [5] Group 6: VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive rating to identify stocks with the best overall potential [6] Group 7: Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988 [7] - The integration of Style Scores with the Zacks Rank helps investors narrow down their choices among over 800 top-rated stocks [8] Group 8: Stock Example - Conmed Corporation - Conmed Corporation, a medical products manufacturer, is currently rated 3 (Hold) on the Zacks Rank with a VGM Score of A [11] - The company has a Momentum Style Score of B, with shares increasing by 8.6% over the past four weeks, and has seen upward revisions in earnings estimates for fiscal 2025 [12]